Phase I Study Evaluating Carbon-Ion Lattice Radiotherapy for Large Thoracic Malignant Tumors

What this Trial Is About

Researchers are evaluating a new treatment approach for patients with unresectable locally advanced non-small cell lung cancer NSCLC and large thoracic malignant solid tumors. This first prospective clinical study aims to assess the safety and effectiveness of induction chemoimmunotherapy followed by carbon ion radiotherapy and consolidation immunotherapy. During the study, tumor tissue, blood, urine, and stool samples will be collected to explore markers that may predict how patients respond to treatment. Participants will receive an experimental treatment called Carbon Ion Lattice Radiation Therapy, which targets large thoracic tumors. This study involves a single treatment group where patients undergo this specialized radiation therapy designed for bulky solid tumors in the chest area. The treatment plan focuses on delivering precise doses of carbon ion radiation to the tumor while aiming to protect surrounding healthy tissue. Throughout the study, participants will be closely monitored for dose-limiting toxicities within 90 days after treatment. Researchers will evaluate safety and treatment effects through regular assessments. Participants must meet specific eligibility requirements, and all will provide informed consent. The study is expected to run until the end of 2028, with ongoing collection and analysis of biological samples to better understand treatment response.

Phase I Study of Carbon-Ion Lattice Radiotherapy for Large Thoracic Tumors